Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products
| Agency: | HEALTH AND HUMAN SERVICES, DEPARTMENT OF |
|---|---|
| State: | Maryland |
| Type of Government: | Federal |
| FSC Category: |
|
| NAICS Category: |
|
| Posted Date: | Jan 14, 2025 |
| Due Date: | Feb 3, 2025 |
| Solicitation No: | 75N95025R00005 |
| Original Source: | Please Login to View Page |
| Contact information: | Please Login to View Page |
| Bid Documents: | Please Login to View Page |
Description
APEX Accelerators are an official government contracting resource for small businesses. Find your local APEX Accelerator (opens in new window) for free government expertise related to contract opportunities.
APEX Accelerators are funded in part through a cooperative agreement with the Department of Defense.
The APEX Accelerators program was formerly known as the Procurement Technical Assistance Program (opens in new window) (PTAP).
- Contract Opportunity Type: Combined Synopsis/Solicitation (Updated)
- Updated Published Date: Jan 14, 2025 01:45 pm EST
- Original Published Date: Nov 30, 2024 04:24 pm EST
- Updated Date Offers Due: Feb 03, 2025 03:00 pm EST
- Original Date Offers Due: Feb 03, 2025 03:00 pm EST
- Inactive Policy: 15 days after date offers due
- Updated Inactive Date: Feb 18, 2025
- Original Inactive Date: Feb 18, 2025
-
Initiative:
- None
- Original Set Aside:
- Product Service Code: AN12 - HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH
-
NAICS Code:
- 325412 - Pharmaceutical Preparation Manufacturing
-
Place of Performance:
Rockville , MD 20850USA
The Therapeutic Development Branch (TDB) within the Division of Preclinical Innovation (DPI) at the National
Center for Advancing Translational Sciences (NCATS) conducts translational research in the area of human
therapeutics development.
The scope of this contract is for Chemistry, Manufacturing, and Control (CMC) services for Drug Products. The
objective of these support services is to ensure receipt of formulated Drug Product (DP) of sufficient quality and quantity to support preclinical, IND-enabling and clinical studies.
The Contractor shall provide support for a broad range of preclinical services required for the design, development,
manufacture, and release of DP, and release of DP as Clinical Trial Material (CTM), including precursors, preliminary
states, Reference Standards (RS) and all required testing. Ancillary products (e.g., placebos, diluents, adjuvants,
master cell banks, testing standards, reference materials) and other materials manufactured or purchased to
support clinical trials or CMC activities may also be required. All activities preliminary to manufacturing in
accordance with current Good Manufacturing Practice (cGMP) may be required (e.g., development or engineering
lots, formulation studies), even without an associated cGMP manufacturing task. All activities required to maintain
material in a usable state, including storage, shipping, testing (in process, release, stability, and quality actions),
and preparation of documents to support regulatory submissions may also be required.
Product formats may include small molecules, short oligomeric compounds, biological (large) molecules,
quaternary molecular assemblies (homogenous or heterogenous), vectors for gene therapy, nanoparticles, and any
of the above modified genetically, biologically, or chemically. Novel formats identified after this draft might also be
needed. Formats could also include Devices or Combination Products. The breadth of this Statement of Work (SOW) includes capabilities to support a range of activities differing in size,
complexity, and duration.
All applicable attachments in connection with this solicitation are available for download.
- c/o 3WFN MSC 6012 301 N Stonestreet Ave
- Bethesda , MD 20892
- USA
- Michelle Cecilia
- michelle.cecilia@nih.gov
- Phone Number 3018277199
- Valerie Whipple
- valerie.whipple@nih.gov
- Phone Number 3018275218
- Jan 14, 2025 01:45 pm ESTCombined Synopsis/Solicitation (Updated)
- Dec 20, 2024 02:46 pm EST Combined Synopsis/Solicitation (Updated)
- Nov 30, 2024 04:24 pm EST Combined Synopsis/Solicitation (Original)
Related Document
| Nov 30, 2024 | [Combined Synopsis/Solicitation (Original)] Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products |
| Dec 20, 2024 | [Combined Synopsis/Solicitation (Updated)] Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products |
| Jul 8, 2026 | [Award Notice (Original)] Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products |
| Jul 8, 2026 | [Award Notice (Original)] Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products |
| Jul 8, 2026 | [Award Notice (Original)] Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products |
| Jul 8, 2026 | [Award Notice (Original)] Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products |
See Also
Follow W56KGU-22-R-0ESI BAA Amendment 0009 Active Contract Opportunity Notice ID W56KGU22ROESI Related Notice
DEPT OF DEFENSE
Due by 10/31/2027
Follow Request for Information (RFI) for Navy Collaborative Combat Aircraft Increment 1 Prototype
DEPT OF DEFENSE
Due by 9/18/2026
Follow Distributed Aperture Resilient Terminal System (DARTS) Active Contract Opportunity Notice ID W56KGU-26-R-0230
DEPT OF DEFENSE
Due by 9/30/2026
Follow Sepsis Research Blood Sample Collection Services Active Contract Opportunity Notice ID HT942523P0084
DEPT OF DEFENSE
Due by 10/15/2026